Technology
Health
Pharmaceutical

AC Immune

$5.58
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.07 (1.27%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell AC Immune and other stocks, options, ETFs, and crypto commission-free!

About ACIU

AC Immune SA Common Stock, also called AC Immune, is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Read More The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Employees
104
Headquarters
Lausanne, Basel-Landschaft (Basle Country)
Founded
2003
Market Cap
372.27M
Price-Earnings Ratio
17.72
Dividend Yield
0.00
Average Volume
287.66K
High Today
$5.87
Low Today
$5.52
Open Price
$5.52
Volume
76.31K
52 Week High
$17.40
52 Week Low
$3.25

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
2016 IPO
Europe (Non-UK)
Europe

ACIU News

Seeking AlphaJun 20

Genentech initiates mid-stage Alzheimer’s study

203

ACIU Earnings

-$0.25
$0.23
$0.72
$1.20
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Available Aug 14, Pre-Market

More ACIU News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.